ExodusPoint Capital Management LP Makes New $358,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

ExodusPoint Capital Management LP acquired a new position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 33,598 shares of the company's stock, valued at approximately $358,000. ExodusPoint Capital Management LP owned 0.14% of UroGen Pharma as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in the business. Barclays PLC lifted its stake in UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company's stock worth $759,000 after acquiring an additional 48,040 shares during the period. JPMorgan Chase & Co. increased its position in shares of UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after buying an additional 49,318 shares during the period. Geode Capital Management LLC lifted its holdings in UroGen Pharma by 8.1% in the third quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after buying an additional 34,248 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of UroGen Pharma by 7.3% during the 4th quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company's stock worth $1,001,000 after acquiring an additional 6,430 shares during the period. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma in the 4th quarter valued at approximately $126,000. 91.29% of the stock is currently owned by institutional investors.

Insider Transactions at UroGen Pharma

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the firm's stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the sale, the insider now owns 145,666 shares in the company, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Jason Drew Smith sold 7,379 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the sale, the general counsel now directly owns 26,468 shares of the company's stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.10% of the stock is currently owned by company insiders.

UroGen Pharma Stock Performance

Shares of NASDAQ URGN traded down $0.72 during midday trading on Thursday, hitting $9.67. 741,549 shares of the stock traded hands, compared to its average volume of 509,086. UroGen Pharma Ltd. has a one year low of $8.94 and a one year high of $20.70. The firm has a 50-day moving average of $10.52 and a two-hundred day moving average of $11.23. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. The firm has a market capitalization of $445.73 million, a P/E ratio of -3.07 and a beta of 0.80.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The company had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. On average, equities analysts forecast that UroGen Pharma Ltd. will post -3.12 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on URGN. The Goldman Sachs Group lowered their target price on shares of UroGen Pharma from $22.00 to $16.00 and set a "neutral" rating for the company in a report on Thursday. HC Wainwright reduced their price target on UroGen Pharma from $64.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price target on the stock. D. Boral Capital restated a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a research note on Monday, March 10th. Finally, Scotiabank began coverage on shares of UroGen Pharma in a research note on Wednesday. They issued a "sector outperform" rating and a $23.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, UroGen Pharma presently has a consensus rating of "Buy" and a consensus target price of $32.86.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.